Skip to content

Study · In silico · 2026

4 results

Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.

Di Napoli M, Morton K, Evensky C, Yoshida C, Baimas-George M, Castle R, Kennealey P, Nydam T, Choudhury R

American journal of surgery15 May 2026Cited by 1 (Europe PMC)

PMID42173727 (opens in a new tab)DOI10.1016/j.amjsurg.2026.117027 (opens in a new tab)PepBankPUB-42173727
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01Computer modelIn silicoEfficacy outcome

    In a Markov model of patients with morbid obesity and stage 5 CKD, tirzepatide and sleeve gastrectomy gave similar survival at pre-intervention BMI below 38 kg/m2.

    In plain wordsIn a computer model of obesity with kidney failure, tirzepatide and sleeve gastrectomy gave similar survival at lower body mass index.

    Peptide
    Tirzepatide
    Outcome
    No significant changeProjected survival, tirzepatide versus sleeve gastrectomy at BMI below 38
    Study

    n = 30,000

    Markov state transition model
    Comparator
    Sleeve gastrectomy
    Outcome group
    Mortality · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients who underwent SG or treatment with tirzepatide experienced similar survival for pre-intervention BMIs below 38 kg/m2.
    1 context sentence
    Summary · context
    A Markov state transition model simulated the life of 30,000 patients with morbid obesity and stage 5 CKD after three weight loss interventions: diet and exercise (DE), sleeve gastrectomy (SG), and tirzepatide treatment.
  2. 02Computer modelIn silicoEfficacy outcome

    In a Markov model of patients with morbid obesity and stage 5 CKD, tirzepatide gave 0.6 fewer projected life-years than sleeve gastrectomy at a BMI of 40 kg/m2.

    In plain wordsIn a computer model, sleeve gastrectomy gave 0.6 more life-years than tirzepatide at a body mass index of 40 in a kidney failure model.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProjected life-years, tirzepatide versus sleeve gastrectomy at BMI 40
    Study

    n = 30,000

    Markov state transition model
    Comparator
    Sleeve gastrectomy
    Outcome group
    Mortality · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Additional life-years with sleeve gastrectomy vs tirzepatide
    0.6 life-years
    BMI 40 kg/m2

    Source sentences

    Summary
    At a BMI of 40 kg/m2, SG was associated with an additional 0.6 life-years relative to tirzepatide, increasing to 3.2 life-years at a BMI of 50 kg/m2.
    1 context sentence
    Summary · context
    A Markov state transition model simulated the life of 30,000 patients with morbid obesity and stage 5 CKD after three weight loss interventions: diet and exercise (DE), sleeve gastrectomy (SG), and tirzepatide treatment.
  3. 03Computer modelIn silicoEfficacy outcome

    In a Markov model of patients with morbid obesity and stage 5 CKD, tirzepatide gave 3.2 fewer projected life-years than sleeve gastrectomy at a BMI of 50 kg/m2.

    In plain wordsIn a computer model, sleeve gastrectomy gave 3.2 more life-years than tirzepatide at a body mass index of 50 in a kidney failure model.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProjected life-years, tirzepatide versus sleeve gastrectomy at BMI 50
    Study

    n = 30,000

    Markov state transition model
    Comparator
    Sleeve gastrectomy
    Outcome group
    Mortality · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Additional life-years with sleeve gastrectomy vs tirzepatide
    3.2 life-years
    BMI 50 kg/m2

    Source sentences

    Summary
    At a BMI of 40 kg/m2, SG was associated with an additional 0.6 life-years relative to tirzepatide, increasing to 3.2 life-years at a BMI of 50 kg/m2.
    1 context sentence
    Summary · context
    A Markov state transition model simulated the life of 30,000 patients with morbid obesity and stage 5 CKD after three weight loss interventions: diet and exercise (DE), sleeve gastrectomy (SG), and tirzepatide treatment.
  4. 04Computer modelIn silicoEfficacy outcome

    In a Markov model of patients with morbid obesity and stage 5 CKD, tirzepatide improved projected survival over diet and exercise at all BMIs above 37 kg/m2.

    In plain wordsIn a computer model of obesity with kidney failure, tirzepatide gave longer survival than diet and exercise at higher body mass index.

    Peptide
    Tirzepatide
    Outcome
    IncreaseProjected survival, tirzepatide versus diet and exercise at BMI above 37
    Study

    n = 30,000

    Markov state transition model
    Comparator
    Diet and exercise
    Outcome group
    Mortality · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    For all BMIs above 37 kg/m2, SG and tirzepatide improved survival over DE.
    1 context sentence
    Summary · context
    A Markov state transition model simulated the life of 30,000 patients with morbid obesity and stage 5 CKD after three weight loss interventions: diet and exercise (DE), sleeve gastrectomy (SG), and tirzepatide treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.